IL261602B2
Antibodies to cd40 with enhanced agonist activity
Abstract
This record has no abstract on file.
Term
No projected expiry on record.
- Priority and filed
- Published
- Today
Every citation, both ways
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| WO03040170A2 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-15 |
| WO2014106015A2 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-15 |
| LI F ET AL,, INHIBITORY FC[GAMMA] RECEPTOR ENGAGEMENT DRIVES ADJUVANT AND ANTI-TUMOR ACTIVITIES OF AGONISTIC CD40 ANTIBODIES, 19 August 2011 (2011-08-19) | Non-patent | – | – | Search report | – |
| WHITE A L ET AL,, INTERACTION WITH FC?RIIB IS CRITICAL FOR THE AGONISTIC ACTIVITY OF ANTI-CD40 MONOCLONAL ANTIBODY, 8 July 2011 (2011-07-08) | Non-patent | – | – | Search report | – |
| RUDIKOFF S ET AL,, SINGLE AMINO ACID SUBSTITUTION ALTERING ANTIGEN-BINDING SPECIFICITY, 1 March 1982 (1982-03-01) | Non-patent | – | – | Search report | – |
30 members in 13 offices
Members30
| Document | Office | Kind | |
|---|---|---|---|
| US2017253659A1 | United States of America | A1 | |
| CA3016534A1 | Canada | A1 | |
| WO2017151176A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2016394956A1 | Australia | A1 | |
| KR20180114223A | Republic of Korea | A | |
| SG11201807677YA | Singapore | A | |
| IL261602A | Israel | A | |
| CN109071655A | China | A | |
| EP3423489A1 | European Patent Office (EPO) | A1 | |
| BR112018067802A2 | Brazil | A2 | |
| EA201891925A1 | Eurasian Patent Organization (EAPO) | A1 | |
| MX2018010672A | Mexico | A | |
| US10894835B2 | United States of America | B2 | |
| US2021139598A1 | United States of America | A1 | |
| CN109071655B | China | B | |
| CN116063494A | China | A | |
| US11760805B2 | United States of America | B2 | |
| IL307425A | Israel | A | |
| US2024026021A1 | United States of America | A1 | |
| IL261602B1 | Israel | B1 | |
| AU2016394956B2 | Australia | B2 | |
| IL261602B2This record | Israel | B2 | |
| AU2024202924A1 | Australia | A1 | |
| EP4406550A2 | European Patent Office (EPO) | A2 | |
| EP3423489B1 | European Patent Office (EPO) | B1 | |
| EP4406550A3 | European Patent Office (EPO) | A3 | |
| ES2985566T3 | Spain | T3 | |
| IL307425B1 | Israel | B1 | |
| IL307425B2 | Israel | B2 | |
| US12577315B2 | United States of America | B2 |
Numbers
- Publication
- 261602
- Application
- 261602
Titles2
- English
- ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY
- Hebrew
- נוגדני CD40 עם פעילות אגוניסטית מוגברת
Classification
- CPC, 15
- C07K16/2878
- A61P35/00
- C07K2317/524
- C07K2317/92
- A61P37/04
- A61K2039/505
- A61P31/12
- C07K2317/73
- C07K2317/515
- C07K2317/21
- C07K2317/52
- C07K2317/51
- C07K2317/72
- C07K2317/75
- C07K2317/522
- IPC, 2
- C07K16 28
- A61K39 00